INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

20251 citationsJournal Articlehybrid Open Access

Authors

This analysis does not support the combination of feladilimab plus pembrolizumab due to a lack of superiority over placebo plus pembrolizumab.

Good health and well-being

Published in: Clinical Cancer Research

Volume 32, Issue 6, pp. 1087-1099

Field-Weighted Citation Impact: 1.02